Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints ...

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of ...

Treatment with emactuzumab has received fast track designation from the United States Food and Drug Administration (FDA) for patients with tenosynovial giant cell tumor (TGCT) who are not amenable to ...

In 83 patients with the non-malignant tumors for whom surgery would potentially worsen functional limitations or cause severe morbidity, the study's primary endpoint showed a 40% overall response ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...

About Tenosynovial Giant Cell Tumor (TGCT) ... Surgery is the main treatment option; however, these tumors tend to recur, particularly in diffuse-type TGCT.

Cassier PA, Italiano A, Gomez-Roca C, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

TURALIO ® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial. Final long-term efficacy and ...

Treatment often involves surgery, ... About Tenosynovial Giant Cell Tumor. Tenosynovial giant cell tumor (TGCT) ... TGCT can result in irreversible damage to the bone, joint and surrounding tissues.